07.02.13
Professor Brendan Buckley has been appointed chief medical officer at ICON plc. Professor Buckley will be ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters, as well as provide guidance and oversight to the medical and scientific groups.
Professor Buckley is an endocrinologist with more than 30 years of experience. He joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and senior vice president of Medical Affairs. He has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards. Mr. Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland.
Ciaran Murray, chief executive officer ICON plc, said, “I would like to congratulate Brendan on his new role and welcome him to ICON’s executive leadership team. Brendan’s wealth of experience both as an advisor to European regulatory agencies and a physician with over 30 years of clinical trial experience, will help us advance our clients' products through their development pipelines and ensure ICON studies continue to be performed to the highest scientific and ethical standards.”
Professor Buckley is an endocrinologist with more than 30 years of experience. He joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and senior vice president of Medical Affairs. He has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards. Mr. Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland.
Ciaran Murray, chief executive officer ICON plc, said, “I would like to congratulate Brendan on his new role and welcome him to ICON’s executive leadership team. Brendan’s wealth of experience both as an advisor to European regulatory agencies and a physician with over 30 years of clinical trial experience, will help us advance our clients' products through their development pipelines and ensure ICON studies continue to be performed to the highest scientific and ethical standards.”